Stock Events

Stock Events

Mabion.

€2.02

0

-€0.02-0.98% Monday 06:11

Statistics

Day High

2.02

Day Low

2.02

52W High

2.65

52W Low

1.68

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

9SepExpected

Q2 2025

999

333

-333

-999

Expected EPS

N/A

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 272.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Biogen is a biotechnology company that develops and markets therapies for neurological and neurodegenerative diseases, competing in the biopharmaceutical sector similar to Mabion.

Amgen is a global biotechnology firm that develops innovative human therapeutics, including in the oncology and inflammation sectors, directly competing with Mabion's therapeutic areas.

Gilead Sciences

Gilead Sciences is a biopharmaceutical company that researches, develops, and commercializes drugs in areas similar to Mabion, particularly in the fields of oncology and viral diseases.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is known for its innovative biopharmaceuticals in areas like oncology, competing directly with Mabion in the development of monoclonal antibodies.

Novartis is a global healthcare company that operates in various therapeutic areas, including those targeted by Mabion, making it a direct competitor in the biopharmaceutical market.

Merck is a global healthcare company that produces medicines, vaccines, biologic therapies, and animal health products, competing in similar therapeutic areas as Mabion.

Pfizer is involved in the discovery, development, and manufacture of healthcare products including medicines and vaccines, directly competing with Mabion in various therapeutic areas.

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses worldwide, with a strong focus on oncology and immunology, overlapping with Mabion's focus areas.

AstraZeneca operates in segments that include oncology, cardiovascular, renal, metabolism, and respiratory, competing with Mabion in the biopharmaceutical and oncology sectors.

Johnson & Johnson

Johnson & Johnson is a comprehensive healthcare firm that produces pharmaceuticals across a broad range of therapeutic areas, including those targeted by Mabion, making it a significant competitor.

About

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.

Show more...

CEO

Mr. Krzysztof Kaczmarczyk

Employees

244

Country

Poland

ISIN

PLMBION00016

Listings

0 Comments

Share your thoughts

FAQ

What is Mabion. stock price today?▼

The current price of 272.MU is €2.02 EUR — it has decreased by -0.98% in the past 24 hours. Watch Mabion. stock price performance more closely on the chart.

What is Mabion. stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Mabion. stocks are traded under the ticker 272.MU.

Is Mabion. stock price growing?▼

272.MU stock has fallen by -2.65% compared to the previous week, the month change is a +3.59% rise, over the last year Mabion. has showed a -7.76% decrease.

How many employees does Mabion. have?▼

As of April 14, 2026, the company has 244 employees.

In which sector is Mabion. located?▼

Mabion. operates in the Health & Wellness sector.

When did Mabion. complete a stock split?▼

Mabion. has not had any recent stock splits.

Where is Mabion. headquartered?▼

Mabion. is headquartered in Konstantynów Lódzki, Poland.